Orion Oyj A
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more
Orion Oyj A (ORNAV) - Net Assets
Latest net assets as of June 2025: €919.60 Million EUR
Based on the latest financial reports, Orion Oyj A (ORNAV) has net assets worth €919.60 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.65 Billion) and total liabilities (€726.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €919.60 Million |
| % of Total Assets | 55.88% |
| Annual Growth Rate | 3.77% |
| 5-Year Change | 37.43% |
| 10-Year Change | 68.94% |
| Growth Volatility | 10.03 |
Orion Oyj A - Net Assets Trend (2004–2024)
This chart illustrates how Orion Oyj A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Orion Oyj A (2004–2024)
The table below shows the annual net assets of Orion Oyj A from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.00 Billion | +12.91% |
| 2023-12-31 | €890.10 Million | -1.98% |
| 2022-12-31 | €908.10 Million | +21.42% |
| 2021-12-31 | €747.90 Million | +2.27% |
| 2020-12-31 | €731.30 Million | -6.17% |
| 2019-12-31 | €779.40 Million | +0.81% |
| 2018-12-31 | €773.10 Million | +13.74% |
| 2017-12-31 | €679.70 Million | +6.02% |
| 2016-12-31 | €641.10 Million | +7.77% |
| 2015-12-31 | €594.90 Million | +15.54% |
| 2014-12-31 | €514.90 Million | +0.19% |
| 2013-12-31 | €513.90 Million | +0.53% |
| 2012-12-31 | €511.20 Million | +2.24% |
| 2011-12-31 | €500.00 Million | +6.97% |
| 2010-12-31 | €467.40 Million | +6.45% |
| 2009-12-31 | €439.10 Million | +4.90% |
| 2008-12-31 | €418.60 Million | -6.42% |
| 2007-12-31 | €447.30 Million | +0.86% |
| 2006-12-31 | €443.50 Million | -23.77% |
| 2005-12-31 | €581.80 Million | +21.28% |
| 2004-12-31 | €479.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orion Oyj A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 181.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €918.20 Million | 91.36% |
| Common Stock | €92.20 Million | 9.17% |
| Other Comprehensive Income | €19.40 Million | 1.93% |
| Total Equity | €1.00 Billion | 100.00% |
Orion Oyj A Competitors by Market Cap
The table below lists competitors of Orion Oyj A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CapitaLand Integrated Commercial Trust
PINK:CPAMF
|
$8.67 Billion |
|
Wintrust Financial Corporation
NASDAQ:WTFC
|
$8.68 Billion |
|
CATHAY PAC.AIRW.HD-20ADR5
F:CTYA
|
$8.70 Billion |
|
Moog Inc
NYSE:MOG-A
|
$8.70 Billion |
|
Exelixis Inc
NASDAQ:EXEL
|
$8.66 Billion |
|
SharkNinja, Inc.
NYSE:SN
|
$8.64 Billion |
|
Brixmor Property
NYSE:BRX
|
$8.61 Billion |
|
Centrica plc
PINK:CPYYF
|
$8.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orion Oyj A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 890,100,000 to 1,005,000,000, a change of 114,900,000 (12.9%).
- Net income of 329,900,000 contributed positively to equity growth.
- Dividend payments of 228,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 19,400,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €329.90 Million | +32.83% |
| Dividends Paid | €228.00 Million | -22.69% |
| Other Comprehensive Income | €19.40 Million | +1.93% |
| Other Changes | €-6.40 Million | -0.64% |
| Total Change | €- | 12.91% |
Book Value vs Market Value Analysis
This analysis compares Orion Oyj A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.57x to 9.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €3.27 | €70.50 | x |
| 2005-12-31 | €4.00 | €70.50 | x |
| 2006-12-31 | €3.14 | €70.50 | x |
| 2007-12-31 | €3.17 | €70.50 | x |
| 2008-12-31 | €2.97 | €70.50 | x |
| 2009-12-31 | €3.11 | €70.50 | x |
| 2010-12-31 | €3.32 | €70.50 | x |
| 2011-12-31 | €3.55 | €70.50 | x |
| 2012-12-31 | €3.63 | €70.50 | x |
| 2013-12-31 | €3.64 | €70.50 | x |
| 2014-12-31 | €3.66 | €70.50 | x |
| 2015-12-31 | €4.22 | €70.50 | x |
| 2016-12-31 | €4.56 | €70.50 | x |
| 2017-12-31 | €4.84 | €70.50 | x |
| 2018-12-31 | €5.50 | €70.50 | x |
| 2019-12-31 | €5.54 | €70.50 | x |
| 2020-12-31 | €5.20 | €70.50 | x |
| 2021-12-31 | €5.32 | €70.50 | x |
| 2022-12-31 | €6.46 | €70.50 | x |
| 2023-12-31 | €6.34 | €70.50 | x |
| 2024-12-31 | €7.15 | €70.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orion Oyj A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 32.83%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 21.39%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 1.62x
- Recent ROE (32.83%) is above the historical average (32.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 19.60% | 4.65% | 1.71x | 2.46x | €44.33 Million |
| 2005 | 23.22% | 6.89% | 1.67x | 2.01x | €74.64 Million |
| 2006 | 15.02% | 21.40% | 0.53x | 1.33x | €22.25 Million |
| 2007 | 32.51% | 21.27% | 1.16x | 1.32x | €100.67 Million |
| 2008 | 32.56% | 19.18% | 1.02x | 1.66x | €94.44 Million |
| 2009 | 34.48% | 19.62% | 1.06x | 1.66x | €107.49 Million |
| 2010 | 39.52% | 21.73% | 1.14x | 1.60x | €137.96 Million |
| 2011 | 41.90% | 22.82% | 1.18x | 1.56x | €159.50 Million |
| 2012 | 40.86% | 21.31% | 1.17x | 1.64x | €157.78 Million |
| 2013 | 40.12% | 20.48% | 1.03x | 1.91x | €154.81 Million |
| 2014 | 41.04% | 20.81% | 1.01x | 1.95x | €159.81 Million |
| 2015 | 35.00% | 20.50% | 0.97x | 1.76x | €148.71 Million |
| 2016 | 38.84% | 23.20% | 1.01x | 1.66x | €184.89 Million |
| 2017 | 33.25% | 20.84% | 1.03x | 1.55x | €158.03 Million |
| 2018 | 42.72% | 33.79% | 0.85x | 1.48x | €252.99 Million |
| 2019 | 25.71% | 19.07% | 1.01x | 1.33x | €122.46 Million |
| 2020 | 30.07% | 20.40% | 0.97x | 1.53x | €146.77 Million |
| 2021 | 25.91% | 18.62% | 0.93x | 1.49x | €119.01 Million |
| 2022 | 38.49% | 26.07% | 0.89x | 1.66x | €258.69 Million |
| 2023 | 24.36% | 18.22% | 0.83x | 1.62x | €127.79 Million |
| 2024 | 32.83% | 21.39% | 0.95x | 1.62x | €229.40 Million |
Industry Comparison
This section compares Orion Oyj A's net assets metrics with peer companies in the Drug Manufacturers - General industry.
No peer company data available for comparison.